Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Milan – page 147

2 391 clinical trials in Milan, Italy across 15 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Milan at a glance
2 391
clinical trials
  • Research sites15
Type of trial
Recruitment status
Quick filters

2 391 trials in Milan

Open in trial search

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Non-small cell lung cancer

Not recruiting

Study of Amivantamab with Carboplatin and Pemetrexed for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Prostate cancer recurrent

Not recruiting

Study on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Janssen Cilag International

Squamous cell carcinoma of head and neck

Not recruiting

Study on Xevinapant and Radiotherapy for High-Risk Head and Neck Cancer Patients Unable to Take High-Dose Cisplatin

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Xevinapant
  • Sponsor:Merck Healthcare KGaA

Gastric cancer+7

Not recruiting

Study on the Safety and Effects of Relatlimab and Nivolumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Hepatocellular carcinoma

Not recruiting

Study of Nivolumab for Patients with Liver Cancer at High Risk of Recurrence After Surgery or Ablation

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Autoimmune haemolytic anaemia

Not recruiting

Long-Term Safety Study of Riliprubart in Patients with Cold Agglutinin Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Bioverativ USA Inc.

Atypical haemolytic uraemic syndrome

Not recruiting

Study on the Effectiveness and Safety of Crovalimab for Children with Atypical Hemolytic Uremic Syndrome (aHUS)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Bladder cancer

Not recruiting

Study on the Effectiveness and Safety of Durvalumab with Gemcitabine and Cisplatin for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Chronic lymphocytic leukaemia

Not recruiting

Study on the Use of Human Normal Immunoglobulin for Preventing Infections in Patients with Chronic Lymphocytic Leukemia and Secondary Immunodeficiency

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Plasma cell myeloma

Not recruiting

Study of Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Milan

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on colorectal cancer, breast cancer prevention, and advanced solid tumors. Studies include evaluation of novel therapeutic approaches and diagnostic methods.

  • Metastatic Colorectal Cancer Treatment
  • Breast Cancer Prevention Strategies
  • Advanced Solid Malignancies

Research emphasizes personalized treatment approaches and preventive interventions for high-risk patients.

02 Neurological Disorders

Research initiatives targeting neurodegenerative conditions and chronic headache disorders, with studies examining innovative therapeutic approaches.

  • Frontotemporal Dementia
  • Parkinson's Disease
  • Migraine Treatment

Focus on developing targeted therapies and understanding disease mechanisms.

03 Immunology and Infectious Diseases

Studies investigating treatments for autoimmune conditions and infectious diseases, including preventive approaches and therapeutic interventions.

  • Immune Thrombocytopenia
  • RSV Prevention
  • HIV Prevention

Emphasis on developing novel preventive strategies and therapeutic solutions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.